Givastomig plus nivolumab and chemo for advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, givastomig, combined with standard immunotherapy (nivolumab) and chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer. It is for people whose tumors have certain markers (CLDN18.2 and PD-L1) and who have not had treatment for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach, gastroesophageal junction, or esophageal adenocarcinoma that cannot be removed by surgery or has spread.
- You have not received treatment for advanced or metastatic disease (prior treatment after surgery is allowed if finished at least 6 months ago).
- Your tumor must have the CLDN18.2 protein and the PD-L1 marker (with CPS score of 1 or higher).
- You are in good physical condition (ECOG score 0 or 1), and your organs are working well.
- You have at least one measurable tumor (per standard guidelines).
- You are able to get pregnant and must use effective birth control, or you are a man agreeing to use birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
This trial tests a new study drug called PF-08634404 in combination with standard chemotherapy for people with stomach, gastroesophageal junction, or esophagus cancer that has spread. It aims to see if adding this drug helps the treatment work better.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
This trial tests a new combination for advanced stomach cancer: an experimental probiotic (EXL01) plus standard immunotherapy (nivolumab) and chemotherapy (FOLFOX). It is for people whose tumors have a high PD-L1 marker and who have not received prior treatment for advanced disease.
This trial tests a new immunotherapy drug (ivonescimab) given with standard chemotherapy before and after surgery for stomach or gastroesophageal junction cancer. The goal is to see if adding this treatment improves outcomes for patients whose cancer has not spread to other organs.
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.